Abstracts tagged "quality and quality improvement"

Abstract Number: 436 • 2016 ACR/ARHP Annual Meeting
Are Providers Recommending Appropriate Screening for Hydroxychloroquine-Induced Retinal Toxicity to Their Patients?
Sarah Haserodt¹, Chris Tonner², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Although well tolerated by most patients, hydroxychloroquine (HCQ) can cause irreversible retinal damage. The American Association of Ophthalmology (AAO) 2016 Guidelines recommend a baseline…
Abstract Number: 2483 • 2015 ACR/ARHP Annual Meeting
Adherence to 2011 American Academy of Ophthalmology Guidelines to Perform Objective Screening Tests for Detection of Antimalarial Retinal Toxicity Is Suboptimal
Sarah Haserodt¹, Chris Tonner², Sara G. Murray³, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/ Rheumatology, UCSF/ San Francisco VA, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, CA
Background/Purpose: American Academy of Ophthalmology (AAO) 2011 guidelines recommend that patients receiving hydroxychloroquine (HCQ) or chloroquine (CQ) undergo regular screening for retinal toxicity with 1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].